BR112022004225A2 - Uso de um inibidor de mdm2 para o tratamento de mielofibrose - Google Patents

Uso de um inibidor de mdm2 para o tratamento de mielofibrose

Info

Publication number
BR112022004225A2
BR112022004225A2 BR112022004225A BR112022004225A BR112022004225A2 BR 112022004225 A2 BR112022004225 A2 BR 112022004225A2 BR 112022004225 A BR112022004225 A BR 112022004225A BR 112022004225 A BR112022004225 A BR 112022004225A BR 112022004225 A2 BR112022004225 A2 BR 112022004225A2
Authority
BR
Brazil
Prior art keywords
myelofibrosis
treatment
mdm2 inhibitor
relates
mdm2
Prior art date
Application number
BR112022004225A
Other languages
English (en)
Inventor
Asa Eliasson
Christophe Meille
Hans Menssen
Gary J Vanasse K
Monika Wroclawska
Nelson Guerreiro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112022004225A2 publication Critical patent/BR112022004225A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

uso de um inibidor de mdm2 para o tratamento de mielofibrose. a presente invenção refere-se ao uso de um inibidor de mdm2 no tratamento de mielofibrose (mf). a invenção também se refere a uma combinação farmacêutica que compreende a) um inibidor de mdm2 e b) pelo menos um agente terapêutico adicional, preferencialmente ruxolitinibe ou um sal farmaceuticamente aceitável do mesmo.
BR112022004225A 2019-09-16 2020-09-14 Uso de um inibidor de mdm2 para o tratamento de mielofibrose BR112022004225A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962900931P 2019-09-16 2019-09-16
PCT/IB2020/058515 WO2021053489A1 (en) 2019-09-16 2020-09-14 Use of an mdm2 inhibitor for the treatment of myelofibrosis

Publications (1)

Publication Number Publication Date
BR112022004225A2 true BR112022004225A2 (pt) 2022-05-31

Family

ID=72603494

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004225A BR112022004225A2 (pt) 2019-09-16 2020-09-14 Uso de um inibidor de mdm2 para o tratamento de mielofibrose

Country Status (12)

Country Link
US (1) US20220331318A1 (pt)
EP (1) EP4031139A1 (pt)
JP (1) JP2022547311A (pt)
KR (1) KR20220063215A (pt)
CN (1) CN114450008A (pt)
AU (1) AU2020351324B2 (pt)
BR (1) BR112022004225A2 (pt)
CA (1) CA3152840A1 (pt)
IL (1) IL290818A (pt)
MX (1) MX2022003129A (pt)
TW (1) TW202123941A (pt)
WO (1) WO2021053489A1 (pt)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101391900B1 (ko) 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
KR101549876B1 (ko) 2007-06-13 2015-09-03 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
SI3050882T1 (en) 2010-03-10 2018-06-29 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives, as inhibitors of JAK1
JO3357B1 (ar) 2012-01-26 2019-03-13 Novartis Ag مركبات إيميدازوبيروليدينون
US20150197525A1 (en) 2012-06-15 2015-07-16 Concert Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
EP3341023A1 (en) * 2015-08-28 2018-07-04 Novartis AG Combination therapy using pi3k inhbitor and mdm2 inhibitor
RU2753527C2 (ru) 2017-03-31 2021-08-17 Новартис Аг ДОЗА И СХЕМА ВВЕДЕНИЯ ИНГИБИТОРА ВЗАИМОДЕЙСТВИЯ HDM2 С p53 ПРИ ГЕМАТОЛОГИЧЕСКИХ ОПУХОЛЯХ
US20210186946A1 (en) * 2018-04-30 2021-06-24 Kartos Therapeutics, Inc. Methods of Treating Cancer
CN112804994A (zh) * 2018-05-25 2021-05-14 卡托斯医疗公司 治疗骨髓增殖性肿瘤的方法

Also Published As

Publication number Publication date
AU2020351324A1 (en) 2022-03-31
EP4031139A1 (en) 2022-07-27
AU2020351324B2 (en) 2023-08-03
CN114450008A (zh) 2022-05-06
US20220331318A1 (en) 2022-10-20
KR20220063215A (ko) 2022-05-17
TW202123941A (zh) 2021-07-01
MX2022003129A (es) 2022-04-06
WO2021053489A1 (en) 2021-03-25
CA3152840A1 (en) 2021-03-25
IL290818A (en) 2022-04-01
JP2022547311A (ja) 2022-11-11

Similar Documents

Publication Publication Date Title
CO2019008487A2 (es) Compuesto de quinazolina
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112018072560A2 (pt) terapia de combinação para tratamento do câncer
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
AR105712A1 (es) Composiciones de insulina de rápida acción
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112022008365A2 (pt) Inibidores de cd73
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
BR112017022653A2 (pt) ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph?
ECSP19016844A (es) Combinación de agonistas de fxr
BR112022026186A2 (pt) Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
CO2022000270A2 (es) Inhibidores de enzimas
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
MX2023004188A (es) Compuestos fosfolipidos y usos de estos.
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
BR112019001130A2 (pt) uso de lactama e composição farmacêutica
CL2020002294A1 (es) Uso de un anticuerpo anti–p–selectina
BR112019004906A2 (pt) combinação incluindo abx196 para o tratamento de câncer
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical